Home/Filings/4/0001209191-22-058172
4//SEC Filing

du Toit Michael 4

Accession 0001209191-22-058172

CIK 0001337553other

Filed

Nov 20, 7:00 PM ET

Accepted

Nov 21, 4:41 PM ET

Size

10.5 KB

Accession

0001209191-22-058172

Insider Transaction Report

Form 4
Period: 2022-11-21
Transactions
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-11-21$9.14/sh16,854$154,0460 total
    Exercise: $6.11Exp: 2032-06-09Common Stock (16,854 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-11-21$1.98/sh7,800$15,4440 total
    Exercise: $13.27Exp: 2030-06-11Common Stock (7,800 underlying)
  • Disposition to Issuer

    Common Stock

    2022-11-21$15.25/sh16,095$245,4490 total
Footnotes (2)
  • [F1]Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes.
  • [F2]Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration.

Issuer

AERIE PHARMACEUTICALS INC

CIK 0001337553

Entity typeother

Related Parties

1
  • filerCIK 0001633208

Filing Metadata

Form type
4
Filed
Nov 20, 7:00 PM ET
Accepted
Nov 21, 4:41 PM ET
Size
10.5 KB